Aditxt and Ignite announce merger plans with strategic partner

Aditxt and subsidiary Ignite Proteomics have announced plans for a business combination with a strategic partner. Ignite will separate from Aditxt and is expected to become an independent public company called Ignite Proteomics. Ignite focuses on developing and commercialising a functional proteomics platform to improve physicians’ understanding of tumours. Credit: Quality Stock Arts / Shutterstock.com. Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m. Upon completion of the transaction, Ignite will separate from…

Source: Pharmaceutical Technology